Synthetic Studies to Help Elucidate the Metabolism of the Preclinical Candidate TBAJ-876—A Less Toxic and More Potent Analogue of Bedaquiline

Bedaquiline is a novel drug approved in 2012 by the FDA for treatment of drug-resistant tuberculosis (TB). Although it shows high efficacy towards drug-resistant forms of TB, its use has been limited by the potential for significant side effects. In particular, bedaquiline is a very lipophilic compo...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Peter J. Choi, Daniel Conole, Hamish S. Sutherland, Adrian Blaser, Amy S.T. Tong, Christopher B. Cooper, Anna M. Upton, Brian D. Palmer, William A. Denny
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2020-03-01
سلاسل:	Molecules
الموضوعات:	bedaquiline tmc207 sirturo bedaquiline analogues tbaj-876 mycobacterium tuberculosis tuberculosis drug development
الوصول للمادة أونلاين:	https://www.mdpi.com/1420-3049/25/6/1423
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!